India, March 11 -- Bioventus Inc. (BVS), a medical device company, on Tuesday reported narrower net loss in its fourth quarter with higher revenues. Adjusted earnings and top line beat market estimates. Further, the company issued fiscal 2025 outlook, expecting earnings and sales above the Street.
In pre-market activity on the Nasdaq, Bioventus shares were gaining around 22.4 percent to trade at $10.72. On Monday's regular trading, the shares had closed 5 percent lower at $8.76.
For the fourth quarter, net loss attributable to the company was $0.17 million, compared to prior year's net loss of $6.10 million.
Net loss from continuing operations was $0.32 million, compared to net loss of $7.66 million in the prior-year period.
There was n...